Camille C Gunderson1, James Java2, Kathleen N Moore3, Joan L Walker4. 1. University of Oklahoma, Department of Obstetrics & Gynecology, Section of Gynecologic Oncology, Oklahoma City, OK, USA. Electronic address: camille-gunderson@ouhsc.edu. 2. Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address: jjava@gogstats.org. 3. University of Oklahoma, Department of Obstetrics & Gynecology, Section of Gynecologic Oncology, Oklahoma City, OK, USA. Electronic address: kathleen-moore@ouhsc.edu. 4. University of Oklahoma, Department of Obstetrics & Gynecology, Section of Gynecologic Oncology, Oklahoma City, OK, USA. Electronic address: joan-walker@ouhsc.edu.
Abstract
OBJECTIVE: To determine the association of body mass index (BMI) on complications, recurrence, and survival in GOG LAP2, a randomized comparison of laparoscopic versus open staging in clinically early stage uterine cancer (EC). METHODS: An ancillary data analysis of GOG LAP2 was performed. Categorical variables were compared using Pearson chi-square test and continuous variables using the Wilcoxon-Mann-Whitney and Kruskal-Wallis tests by BMI group. Survival was estimated using the Kaplan-Meier method. Cox proportional hazards model was used to evaluate independent prognostic factors on survival. Statistical tests were two-tailed with α=0.05, except where noted. Statistical analyses utilized R programming language. RESULTS:2596 women were included. BMI (kg/m(2)) groups were <25 (29.5%), 25-30 (28.2%), 30-35 (21%), 35-40 (10.9%), and ≥40 (10.4%). Stage (p=0.021), grade (p<0.001), and histology (p=0.005) differed by BMI. Obese women were less likely to have high risk (HR) disease (+lymph nodes/ovaries/cytology) or tumor features that met GOG99 high intermediate risk (HIR) criteria (p<0.001). Adjuvant therapy (p=0.151) and recurrence (p=0.46) did not vary by BMI. Hospitalization >2days, antibiotic use, wound infection, and venous thrombophlebitis were higher with BMI ≥40. BMI (p=0.016), age (p<0.0001), race (p=0.033), and risk group (p<0.0001) predicted all-cause mortality. BMI was not predictive of disease-specific survival (p=0.79), but age (p=0.032) and risk group (p<0.0001) were significant factors. CONCLUSION:Obese women have greater surgical risk and lower risk of metastatic disease. BMI is associated with all-cause but not disease-specific mortality, emphasizing the detrimental effect of obesity (independent of EC), which deserves particular attention.
RCT Entities:
OBJECTIVE: To determine the association of body mass index (BMI) on complications, recurrence, and survival in GOG LAP2, a randomized comparison of laparoscopic versus open staging in clinically early stage uterine cancer (EC). METHODS: An ancillary data analysis of GOG LAP2 was performed. Categorical variables were compared using Pearson chi-square test and continuous variables using the Wilcoxon-Mann-Whitney and Kruskal-Wallis tests by BMI group. Survival was estimated using the Kaplan-Meier method. Cox proportional hazards model was used to evaluate independent prognostic factors on survival. Statistical tests were two-tailed with α=0.05, except where noted. Statistical analyses utilized R programming language. RESULTS: 2596 women were included. BMI (kg/m(2)) groups were <25 (29.5%), 25-30 (28.2%), 30-35 (21%), 35-40 (10.9%), and ≥40 (10.4%). Stage (p=0.021), grade (p<0.001), and histology (p=0.005) differed by BMI. Obese women were less likely to have high risk (HR) disease (+lymph nodes/ovaries/cytology) or tumor features that met GOG99 high intermediate risk (HIR) criteria (p<0.001). Adjuvant therapy (p=0.151) and recurrence (p=0.46) did not vary by BMI. Hospitalization >2days, antibiotic use, wound infection, and venous thrombophlebitis were higher with BMI ≥40. BMI (p=0.016), age (p<0.0001), race (p=0.033), and risk group (p<0.0001) predicted all-cause mortality. BMI was not predictive of disease-specific survival (p=0.79), but age (p=0.032) and risk group (p<0.0001) were significant factors. CONCLUSION: Obese women have greater surgical risk and lower risk of metastatic disease. BMI is associated with all-cause but not disease-specific mortality, emphasizing the detrimental effect of obesity (independent of EC), which deserves particular attention.
Authors: Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg Journal: Oncologist Date: 2019-06-11
Authors: Rudy S Suidan; Weiguo He; Charlotte C Sun; Hui Zhao; Nicole D Fleming; Pedro T Ramirez; Pamela T Soliman; Shannon N Westin; Karen H Lu; Sharon H Giordano; Larissa A Meyer Journal: Gynecol Oncol Date: 2017-01-26 Impact factor: 5.482
Authors: Laura R Daily; Jonathan D Boone; Hannah C Machemehl; Eric D Thomas; Gerald McGwin; J Michael Straughn; Charles A Leath Journal: Int J Gynecol Cancer Date: 2017-05 Impact factor: 3.437
Authors: Z M Gambacorti-Passerini; C López-De la Manzanara Cano; C Pérez Parra; M C Cespedes Casas; L Sánchez Hipólito; C Martín Francisco; J R Muñoz-Rodríguez Journal: Obes Surg Date: 2019-10 Impact factor: 4.129
Authors: Mario M Leitao; Wazim R Narain; Donna Boccamazzo; Vasileios Sioulas; Danielle Cassella; Jennifer A Ducie; Ane Gerda Z Eriksson; Yukio Sonoda; Dennis S Chi; Carol L Brown; Douglas A Levine; Elizabeth L Jewell; Oliver Zivanovic; Richard R Barakat; Nadeem R Abu-Rustum; Ginger J Gardner Journal: Ann Surg Oncol Date: 2016-01-07 Impact factor: 5.344
Authors: Ashley S Felix; D Scott McMeekin; David Mutch; Joan L Walker; William T Creasman; David E Cohn; Shamshad Ali; Richard G Moore; Levi S Downs; Olga B Ioffe; Kay J Park; Mark E Sherman; Louise A Brinton Journal: Gynecol Oncol Date: 2015-09-01 Impact factor: 5.482
Authors: Ross Harrison; Maria D Iniesta; Brandelyn Pitcher; Pedro T Ramirez; Katherine Cain; Ashley M Siverand; Gabriel Mena; Javier Lasala; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2020-08-26 Impact factor: 3.437